What's important

here? The patient results detailed on this infographic are mostly men who are middle aged and only slightly overweight (BMI>25).

ee Arthritis



Patient Demographics

| | Regenexx-SD |
|--------|--------------------|
| N | 999 procedures |
| Male | 604 (60.5%) |
| Female | 395 (39.5%) |
| Age | 55.5 (13-92) |
| Height | 68.1"(49-83) |
| Weight | 177 (100-315) lbs. |
| BMI | 26.8 (16-55.8) |

Caution! This is registry data, which is not the same as a controlled trial. This means it was collected as patients were treated.


This data analysis is part of the fall 2014 data download of patients who were tracked in our advanced registry. For the 2012 version (with fewer patients included), click here, for the 2013 version (click here). More information can be found at the links below:

- How about functional questionnaire data on knees?
- What decisions that can be made based on this registry data. For example does age or arthritis severity impact outcomes?

Fall 2014 Data



Regenexx-SD is a same day stem cell procedure where cells are harvested in the morning and placed back in the afternoon.



What do these two graphs mean? The graph above represents the percentage of patients who reported >50% relief at various time points after the procedure. For example, at 36 months almost 80% of patients who responded reported more than 50% relief. For the graph below, this is the mean reported relief at these same time points. For example, patients at 12 months may have reported anything from no relief, to 50% relief, to 90% relief the mean of all of those reports was 53% improved..



For demographics, N for age calculation was 998, for BMI 925. Numbers of patients followed up for outcomes were the following: 461 at 1 month, 444 at 3 months, 371 at 6 month, 232 at 12 months, 154 at 18 at months, 100 at 24 at months and 47 at 36 months, 10 at 48 months. The expected follow-up Ns were: 928 at 1 month, 838 at 3 months, 699 at 6 months, 447 at 12 months, 307 at 18 months, 211 at 24 months, 97 at 36 months, 20 at 48 months. There we 67 study exits during the 4 year period, with 19 due to TKA. It also should be noted that 7 of the 35 patients due to report at 4 years had reported needing a TKA. Study exits were not counted above in the expected follow-up Ns at any given time point as they had refused additional follow-up.